A previous study demonstrated that the mean tumor burden and median survival for patients with mutations of N-ras was indistinguishable from patients with no RAS mutations; on the other hand, patients with K-ras mutations had a significantly higher mean bone marrow tumor burden at diagnosis than patients with no ras mutations [38]. This evidence concerns the gene NRAS and neoplasm.